Yeah, thanks for having us Liisa, and it’s always fun to be at this conference, which we’ve been doing for the last four years. I think it’s a space that’s evolving quite rapidly with CRISPR. I think ...
Following the approval of the advanced therapy Casgevy late last year, CRISPR Therapeutics has validated its CRISPR-Cas9 gene editing platform in record time. Now, enjoying multiple tailwinds thanks ...
Hi, it's Tony Butler from ROTH Capital. I appreciate you joining us this afternoon. I have the distinct pleasure this afternoon to introduce Sam Kulkarni from CRISPR Therapeutics. CRISPR, I think, is ...
All right, thanks everybody for dialing in. My name is Raju Prasad, I am the Research Analyst at William Blair, who covers CRISPR Therapeutics. I am required to inform you that for a complete list of ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of ...
BASEL, Switzerland and CAMBRIDGE, Massachusetts – August 11, 2015 – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into cures for serious ...
Good morning. My name is Ted Tenthoff. I'm a Senior Biotechnology Analyst at Piper Sandler, and welcome to our Virtual Healthcare Conference. CRISPR is the leading developer of CRISPR Cas9 therapies, ...
Follow this author to personalize your feed and get instant alerts. WHY FOLLOW? Custom Feed: See the stories that matter most to you. Smart Alerts: Get notified about major news as it happens. Update ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results